0 662

Cited 7 times in

Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome

Authors
 Ahn J.-S.  ;  Kim Y.-K.  ;  Min Y.H.  ;  Cheong J.-W.  ;  Jang J.H.  ;  Jung C.W.  ;  Kim I.H.  ;  Yoon H.-J.  ;  Lee H.G.  ;  Sohn S.K.  ;  Moon J.H.  ;  Kim H.h  ;  Kim Y.-J.  ;  Won J.-H.  ;  Chung J.-S.  ;  Mun Y.C.  ;  Lee J.-H.  ;  Kim H.-J. 
Citation
 ACTA HAEMATOLOGICA, Vol.134(1) : 40-48, 2015 
Journal Title
ACTA HAEMATOLOGICA
ISSN
 0001-5792 
Issue Date
2015
MeSH
Adolescent ; Adult ; Allografts ; Antimetabolites, Antineoplastic* ; Azacitidine*/administration & dosage ; Azacitidine*/adverse effects ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Myelodysplastic Syndromes*/mortality ; Myelodysplastic Syndromes*/pathology ; Myelodysplastic Syndromes*/therapy ; Prospective Studies ; Stem Cell Transplantation* ; Survival Rate
Keywords
Myelodysplastic syndrome ; Azacitidine ; Allogeneic stem cell transplantation
Abstract
Azacitidine (AZA) is commonly used in patients with myelodysplastic syndrome (MDS). To determine the role of AZA before allogeneic stem cell transplantation (allo-SCT), we conducted a prospective study of AZA pre-treatment followed by allo-SCT in patients with higher-risk MDS. Twenty-one patients who were scheduled for their third to sixth cycle of AZA pre-treatment followed by allo-SCT were enrolled. AZA pre-treatment was interrupted early in 3 patients (14.3%) because of leukaemic transformation or death. The overall response rate to AZA pre-treatment was 57.1%. There were 2 cases of complete remission, 1 case of partial remission, and 9 cases of haematologic improvement. Fourteen patients (66.7%) received the planned allo-SCT and 5 patients were alive at the last follow-up. Three-year progression-free survival (PFS) and 3-year overall survival (OS) in the 14 patients who received allo-SCT were 30.0% (95% CI 3.3-56.7) and 42.9% (95% CI 17.1-68.7), respectively. PFS and OS were not influenced by response to AZA pre-treatment (p > 0.05). In this study, AZA had a role as a bridge therapy to prevent leukaemic transformation prior to selection of a donor for allo-SCT and showed low toxicity. It may be considered in patients with higher-risk MDS.
Full Text
http://www.karger.com/Article/FullText/368711
DOI
10.1159/000368711
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Min, Yoo Hong(민유홍) ORCID logo https://orcid.org/0000-0001-8542-9583
Cheong, June-Won(정준원) ORCID logo https://orcid.org/0000-0002-1744-0921
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/141264
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links